Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (NCT04989803)
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- Stanford Cancer Institute — Stanford, California
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
- Northside Hospital — Atlanta, Georgia
- Midwestern Regional Medical Center, Inc.City of Hope Chicago — Park Ridge, Illinois
- Norton Cancer Institute, St. Matthews Campus — Shelbyville, Kentucky
- University of MD, Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
- Mayo Clinic — Rochester, Minnesota
- Hackensack University Medical Center — Hackensack, New Jersey
- Columbia University Irving Medical Center — New York, New York
- University of Rochester Medical Center — Rochester, New York
- The Ohio State University Wexner Medical Center - James Cancer Hospital — Columbus, Ohio
- Tennessee Oncology, PLLC - Investigational Drug Services — Nashville, Tennessee
- Vanderbilt University — Nashville, Tennessee
- St. David's Medical Center — Austin, Texas
- The University of Texas, MD Anderson Cancer Center — Houston, Texas
- Virginia Oncology Associates — Norfolk, Virginia
- Royal North Shore Hospital — St Leonards, New South Wales
- Concord Repatriation General Hospital — Sydney, New South Wales
- Royal Adelaide Hospital — Adelaide, South Australia
- Epworth Healthcare — East Melbourne, Victoria
- Jewish General Hospital — Montreal,
- McGill University Health Center — Montreal,
📞 Contact the Study Coordinator
Phone: 844-454-5483(1-844-454-KITE)
Email: medinfo@kitepharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Relapsed and/or Refractory B-cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.